

Meningococcus (Neisseria meningitidis Infection) Drug Development Pipeline Study, H2 2018

<https://marketpublishers.com/r/M51BFC7FEE9EN.html>

Date: August 2018

Pages: 65

Price: US\$ 1,200.00 (Single User License)

ID: M51BFC7FEE9EN

Abstracts

Meningococcus (Neisseria meningitidis Infection) Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Meningococcus (Neisseria meningitidis Infection) pipeline products.

DISEASE OVERVIEW

Meningococcal infection is one of the serious and death causing infections worldwide. In particular, Sub-Saharan Africa frequently witnesses meningococcus outbreaks with 1 person per 100 being infected. In rest of the world, the prevalence is at an estimated 0.3 to 3 per 100,000 people.

The infection is caused by the bacteria *Neisseria meningitidis* and affects the human spinal cord, lining of brain. Purulent spinal fluid or detection of the bacteria in the fluid or blood is currently used to determine the meningococcus infected persons.

Meningococcal vaccines vary largely in price from around \$2.5 to \$117 per dose. Currently available vaccines include bivalent, trivalent and tetravalent. Further, the disease has high fatality rates of around 50% if left untreated.

Accordingly, to increase their share in global meningococcus market, companies are aggressively investing their financial and R&D efforts in meningococcal infection pipeline. 10+ companies are participating in the pipeline development of meningococcus, which include Beijing Minhai Biotechnology Co Ltd, Biological E Ltd, Chongqing Zhifei Biological Products Co Ltd, GlaxoSmithKline Plc, ImmunoBiology Ltd, Neoculi Pty Ltd, Pfizer Inc, Sanofi Pasteur SA, Serum Institute of India Ltd, Tianjin CanSino Biotechnology Inc, Wellstat Vaccines LLC.

REPORT DESCRIPTION

The Meningococcus (Neisseria meningitidis Infection) pipeline guide presents complete overview of drugs currently being developed for Meningococcus (Neisseria meningitidis Infection). The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Meningococcus (Neisseria meningitidis Infection) pipeline candidate.

Research and Development progress along with latest news related to each of the Meningococcus (Neisseria meningitidis Infection) pipeline candidates is included.

Major companies participating in therapeutic development of Meningococcus (Neisseria meningitidis Infection) are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Meningococcus (Neisseria meningitidis Infection) from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Meningococcus (Neisseria meningitidis Infection) clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Meningococcus (Neisseria meningitidis Infection) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF MENINGOCOCCUS (NEISSERIA MENINGITIDIS INFECTION) PIPELINE REPORT INCLUDES

Panorama of Meningococcus (Neisseria meningitidis Infection) pipeline markets

including statistics on therapeutic drugs and companies involved

Meningococcus (Neisseria meningitidis Infection) Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered

Meningococcus (Neisseria meningitidis Infection) pipeline candidates across various 'Mechanism of Actions' are also presented in the study

Overview of companies participating in Meningococcus (Neisseria meningitidis Infection) pipeline with short introduction to their businesses and pipeline projects

For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.

Research and Development progress and trial details, results wherever available, are also included in the pipeline study

The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Meningococcus (Neisseria meningitidis Infection) pipeline therapeutics

REASONS TO BUY

Get clear understanding of the entire Meningococcus (Neisseria meningitidis Infection) pipeline, with details on active projects

Get in detail information of each product with updated information on each project along with key milestones

Know the list of companies participating in global Meningococcus (Neisseria meningitidis Infection) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and

company

Contents

I. KEY FINDINGS

1. Companies Investing in Meningococcus Pipeline include-
 - Number of Companies with Meningococcus projects in pre-clinical Development-
 - Number of Companies with Meningococcus projects in Clinical Development-
 - Meningococcus Pipeline Companies based in Americas
 - Meningococcus Pipeline Companies based in Europe
 - Meningococcus Pipeline Companies based in Asia Pacific
 - Meningococcus Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
 - Meningococcus Pipeline Agents in pre- clinical/Discovery stage of Development
 - Meningococcus Pipeline Agents in Clinical Development stage
 - Meningococcus Pipeline Therapeutic Compounds received special status
 - Mechanism of Action of most pipeline Drugs-
 - Small molecules among the Meningococcus Pipeline agents

II. INSIGHTS INTO MENINGOCOCCUS PIPELINE

1. Disease Overview
 - Introduction to Meningococcus
 - Symptoms and Causes of Meningococcus
 - Treatment or Prevention Options for Meningococcus
 - Other Details
2. Phase wise Pipeline Compounds
 - Meningococcus Pipeline- Pre- Clinical/Discovery stage Drugs
 - Meningococcus Pipeline- Phase 1 stage Drugs
 - Meningococcus Pipeline- Phase 2 stage Drugs
 - Meningococcus Pipeline- Phase 3 stage Drugs
 - Meningococcus Pipeline- Pre-Registration stage Drugs
3. Company wise Meningococcus Pipeline Compounds
4. Meningococcus Pipeline by Mechanism of Action

III. MENINGOCOCCUS PIPELINE COMPOUND DETAILS

Meningococcal (A,C,Y, W135) tetra valent vaccine
meningococcal A, C, W, Y vaccine
A, C, Y, W135 meningococcal polysaccharide conjugate vaccine

ABC Meningococcal Vaccine

Men ABCWY

MenBioVax

NCL195

PF-06886992

Men Quad TT

Pentavalent Meningococcal Conjugate Vaccine (A, C, Y, W-135, X)

MCV2

Meningococcus B synthetic oligosaccharide conjugate Vaccine

Meningococcus CY polysaccharide conjugate Vaccine

Drug Details

1. Snapshot

Name of the Therapeutic Agent

Originator

Developing Company

Co-Developer/License Partner

Orphan Drug/Fast Track/Designation

Development Phase

2. Drug Overview

3. Mechanism of Action

4. Current Status

5. Clinical Trial Details

IV. MENINGOCOCCUS PIPELINE COMPANY BRIEFS

Beijing Minhai Biotechnology Co Ltd

Biological E Ltd

Chongqing Zhifei Biological Products Co Ltd

GlaxoSmithKline Plc

ImmunoBiology Ltd

Neoculi Pty Ltd

Pfizer Inc

Sanofi Pasteur SA

Serum Institute of India Ltd

Tianjin CanSino Biotechnology Inc

Wellstat Vaccines LLC

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL MENINGOCOCCUS PIPELINE MARKET

VI. APPENDIX

1. Publisher's Expertise
2. Research Methodology
3. Contact Information

Some of the sections depicted above may be removed or modified on the basis of information availability

I would like to order

Product name: Meningococcus (Neisseria meningitidis Infection) Drug Development Pipeline Study, H2 2018

Product link: <https://marketpublishers.com/r/M51BFC7FEE9EN.html>

Price: US\$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M51BFC7FEE9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

